Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2020 Oct:99:229-230.
doi: 10.1016/j.ijid.2020.07.065. Epub 2020 Aug 7.

Clinical immunity in discharged medical patients with COVID-19

Nicola Mumoli  1 , Josè Vitale  2 , Antonino Mazzone  2
Affiliations
Multicenter Study

Clinical immunity in discharged medical patients with COVID-19

Nicola Mumoli et al. Int J Infect Dis. 2020 Oct.

Abstract

Background: Most studies on SARS-CoV-2 infection show that people who have recovered from COVID-19 have antibodies to the virus. No study has evaluated whether the presence of antibodies to SARS-CoV-2 confers immunity to the infection relapse but however, to date, no human reinfections with SARS-CoV-2 have been confirmed.

Material and methods: In our prospective, multicenter, cohort study we investigated within three months all patients, with confirmed COVID-19, discharged from two Hospitals (Legnano and Magenta Hospitals), in an area of Italy severely affected by the infection. Telephone follow-up at 1 and 2 months and clinical contact within 3 months was initiated; demographic, clinical, radiologic and laboratory data were recorded in electronic medical records and updated.

Results: Of 1081 patients involved, 804 (74.3%) were discharged alive. For all these patients we obtained follow-up data. At 1 and 2 months none has died and none has had any signs of recurrence of infectious at both telephone interview and clinical visit.

Conclusion: Our clinical observation have confirmed two basic points: the reinfection is very unlikely and any antibody immunity protects against recurrence, at least in the short term.

Keywords: COVID-19; Immunity; SARS-CoV-2.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cohort and follow-up. ★ Major gastrointestinal bleeding during anticoagulant therapy (n = 3), acute ischemic stroke (n = 2), NSTEMI (n = 2), urinary sepsis (n = 4), chronic obstructive pulmonary disease exacerbation (n = 5), heart failure (n = 4), diabetic ketoacidosis (n = 1), delirium psychosis (n = 3).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kirkcaldy R.D., King B.A., Brooks B.A. COVID-19 and postinfection immunity: limited evidence, many remaining questions. JAMA. 2020 doi: 10.1001/jama.2020.7869. - DOI - PMC - PubMed
    1. World Health Organization . WHO Scientific Brief 24 April; 2020. “Immunity passports” in the context of COVID-19.
    1. Zhou G., Zhao Q. Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2. Int J Biol Sci. 2020;16(10):1718–1723. - PMC - PubMed

Publication types

Substances